NewsBenzingaDorman Products Narrows FY2026 Adj EPS Guidance from $8.50-$8.80 to $8.50-$8.70 vs $8.66 Est; Sees Sales $2.173B-$2.194B vs $2.211B Est Dorman Products Narrows FY2026 Adj EPS Guidance from $8.50-$8.80 to $8.50-$8.70 vs $8.66 Est; Sees Sales $2.173B-$2.194B vs $2.211B Est Benzinga 2026.10.26 20:30 (GMT+0) Open on Benzinga Other news Ascent Industries Q3 EPS $0.15 Up From $(0.01) YoY, Sales $27.135M Up From $19.697M YoY Agilon Health Q3 EPS $1.97 Beats $(1.46) Estimate, Sales $1.519B Beat $1.461B Estimate UPDATE: Edwards Lifesciences Raises FY2026 Adj EPS Guidance from $2.95-$3.05 to $2.97-$3.05 vs $3.00 Est; Narrows FY2026 Sales Guidance from $6.600B-$6.900B to $6.766B vs $6.767B Est Accuray Announces 1-For-40 Reverse Stock Split, Effective Nov. 9 Enact Holdings Q3 Adj. EPS $1.19 Beats $1.18 Estimate, Sales $312.854M Miss $317.921M Estimate Maravai LifeSciences Raises FY2026 Sales Guidance from $205.000M-$215.000M to $212.000M-$216.000M vs $211.767M Est
UPDATE: Edwards Lifesciences Raises FY2026 Adj EPS Guidance from $2.95-$3.05 to $2.97-$3.05 vs $3.00 Est; Narrows FY2026 Sales Guidance from $6.600B-$6.900B to $6.766B vs $6.767B Est
Maravai LifeSciences Raises FY2026 Sales Guidance from $205.000M-$215.000M to $212.000M-$216.000M vs $211.767M Est
